Cargando…

SAT-LB16 Maintenance of Favorable Treatment Effect of Once-Weekly TransCon hGH for Children With Growth Hormone Deficiency: Interim Analysis From the Enlighten Long-Term Extension Trial

Background Once-weekly TransCon hGH is an investigational long-acting prodrug for growth hormone deficiency (GHD) that consists of 3 components: unmodified growth hormone (hGH; somatropin), an inert carrier that protects it, and a linker that temporarily binds the two. In the randomized phase 3 heiG...

Descripción completa

Detalles Bibliográficos
Autores principales:	Maniatis, Aristides K, Casella, Samuel J, Nadgir, Ulhas M, Mick, Gail J, Hofman, Paul, Saenger, Paul, Chertok, Elena D, Warshauer, Jeremy, Song, Wenjie, Peng, Jessica M, Komirenko, Allison S, Shu, Aimee D, Beckert, Michael, Aghajanova, Elena M, Thornton, Paul S
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2020
Materias:	Pediatric Endocrinology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7209480/ http://dx.doi.org/10.1210/jendso/bvaa046.2102

Ejemplares similares

Efficacy and Safety of up to 2 Years of Treatment With TransCon hGH (Lonapegsomatropin) in Treatment-Naïve and Treatment-Experienced Children With Growth Hormone Deficiency
por: Maniatis, Aristides K, et al.
Publicado: (2021)

OR10-05 Phase 3 FliGHt Trial: Experience of Switching from Daily Growth Hormone Therapy to Once-Weekly TransCon HGH in Children with Growth Hormone Deficiency
por: Maniatis, Aristides K, et al.
Publicado: (2020)

RF26 | PMON332 Safety and Efficacy of Treatment with Lonapegsomatropin in Children with Growth Hormone Deficiency at Week 130 in the enliGHten Trial
por: Saenger, Paul, et al.
Publicado: (2022)

Safety and Efficacy of Lonapegsomatropin in Children With Growth Hormone Deficiency: enliGHten Trial 2-Year Results
por: Maniatis, Aristides K, et al.
Publicado: (2022)

THU173 Subanalysis By Tanner Stage In Phase 3 Trials In Children And Adolescents With Growth Hormone Deficiency Treated With Lonapegsomatropin
por: Hofman, Paul, et al.
Publicado: (2023)

OR17-4 Transcon Growth Hormone In The Treatment Of Pediatric Growth Hormone Deficiency: Results Of The Phase 3 Height Trial
por: Thornton, Paul, et al.
Publicado: (2019)

Design of the ForesiGHt Trial: A Multicenter, Randomized, Placebo- and Active-Controlled Trial to Compare Once-Weekly TransCon hGH (lonapegsomatropin) to Placebo and Daily Somatropin in Adults With Growth Hormone Deficiency (GHD)
por: Fleseriu, Maria, et al.
Publicado: (2021)

Switching to Weekly Lonapegsomatropin from Daily Somatropin in Children with Growth Hormone Deficiency: The fliGHt Trial
por: Maniatis, Aristides K., et al.
Publicado: (2022)

What Factors Spur a Short Individual's Response to Human GH (hGH)?
por: Rogol, Alan D
Publicado: (2023)

Intranasal Human Growth Hormone (hGH) Induces IGF-1 Levels Comparable With Subcutaneous Injection With Lower Systemic Exposure to hGH in Healthy Volunteers
por: Lewis, Andrew L., et al.
Publicado: (2015)

A phase 2 trial of long-acting TransCon growth hormone in adult GH deficiency
por: Höybye, Charlotte, et al.
Publicado: (2017)

Adherence to r-hGH Therapy in Pediatric Growth Hormone Deficiency: Current Perspectives on How Patient-Generated Data Will Transform r-hGH Treatment Towards Integrated Care
por: Savage, Martin O, et al.
Publicado: (2022)

Preclinical and Clinical In Vitro In Vivo Correlation of an hGH Dextran Microsphere Formulation
por: Vlugt-Wensink, K. D. F., et al.
Publicado: (2007)

Adherence in children with growth hormone deficiency treated with r-hGH and the easypod™ device
por: Loche, S., et al.
Publicado: (2016)

Cell-specific expression of alpha 1(I) collagen-hGH minigenes in transgenic mice
Publicado: (1994)

Testosterone, cortisol, hGH, and IGF‐1 levels in an Italian female elite volleyball team
por: Roli, Laura, et al.
Publicado: (2018)

PLGA Microspheres of hGH of Preserved Native State Prepared Using a Self-Regulated Process
por: Diana, Jebun Nessa, et al.
Publicado: (2020)

SUN-464 Trunk Fat Increase Is Prevented Both in Patients Undergoing Long-Lasting Continuous r-hGH Therapy and in Those Who Discontinued r-hGH Compared to Untreated Patients: Results from Baseline Data of the MAGHD Study
por: Monzani, Maria Laura, et al.
Publicado: (2019)

Easypod(TM) adherence in children with growth disorders treated with r-hGH. A preliminary Italian experience
por: Loche, Sandro, et al.
Publicado: (2013)

Isolation and Characterization of the Arapaima gigas Growth Hormone (ag-GH) cDNA and Three-Dimensional Modeling of This Hormone in Comparison with the Human Hormone (hGH)
por: Lima, Eliana Rosa, et al.
Publicado: (2023)

OP Transcon 2018 Compilation
Publicado: (2019)

PP Transcon 2018 Compilation
Publicado: (2019)

Solid-Phase Synthesis of an “Inaccessible” hGH-Derived Peptide Using a Pseudoproline Monomer and SIT-Protection for Cysteine
por: Manne, Srinivasa Rao, et al.
Publicado: (2022)

PMON68 Effect of an Amino-Acid Based Blend on Human Growth Hormone (hGH) and Fibromyalgia (FM) Symptoms
por: Beres, Adam, et al.
Publicado: (2022)

Autocrine hGH stimulates oncogenicity, epithelial-mesenchymal transition and cancer stem cell-like behavior in human colorectal carcinoma
por: Wang, Jing-Jing, et al.
Publicado: (2017)

TRANSCON 2022 B: Poster Papers
Publicado: (2023)

TRANSCON 2022 B: Oral Abstracts
Publicado: (2023)

Iontophoretic Transdermal Delivery of Human Growth Hormone (hGH) and the Combination Effect of a New Type Microneedle, Tappy Tok Tok(®)
por: Noh, Gyubin, et al.
Publicado: (2018)

Extensive phenotypic characterization of a new transgenic mouse reveals pleiotropic perturbations in physiology due to mesenchymal hGH minigene expression
por: Kaklamanos, Aimilios, et al.
Publicado: (2017)

OR10-04 Interpretation of Insulin-like Growth Factor-1 (IGF-1) Levels Following Administration of Somatrogon (a Long-acting Human Growth Hormone - hGH-CTP)
por: Fisher, Dennis M, et al.
Publicado: (2020)

Response to Letter to the Editor From Malozowski: “Weekly Lonapegsomatropin in Treatment-Naïve Children With Growth Hormone Deficiency: The Phase 3 heiGHt Trial”
por: Thornton, Paul S, et al.
Publicado: (2021)

SAT-LB72 Design of the PaTH Forward Phase 2 Trial of TransCon PTH, a Long-Acting PTH, in Patients With Hypoparathyroidism
por: Khan, Aliya Aziz, et al.
Publicado: (2020)

Cost-consequence analysis for human recombinant growth hormone (r-hGH) treatment administered via different devices in children with growth hormone deficiency in Italy
por: Foo, Jason, et al.
Publicado: (2019)

Weekly Lonapegsomatropin in Treatment–Naïve Children With Growth Hormone Deficiency: The Phase 3 heiGHt Trial
por: Thornton, Paul S, et al.
Publicado: (2021)

Response to Letter to the Editor From L. Sävendahl et al: “Weekly Lonapegsomatropin in Treatment-Naïve Children With Growth Hormone Deficiency: The Phase 3 heiGHt Trial”
por: Thornton, Paul S, et al.
Publicado: (2021)

Effective GH Replacement With Once-weekly Somapacitan vs Daily GH in Children with GHD: 3-year Results From REAL 3
por: Sävendahl, Lars, et al.
Publicado: (2021)

38(th) ISBTI Annual Conference, TRANSCON 2013, Surat
Publicado: (2014)

Once-Weekly Somapacitan vs Daily GH in Children With GH Deficiency: Results From a Randomized Phase 2 Trial
por: Sävendahl, Lars, et al.
Publicado: (2020)

Investigations into the In Vitro Metabolism of hGH and IGF-I Employing Stable-Isotope-Labelled Drugs and Monitoring Diagnostic Immonium Ions by High-Resolution/High-Accuracy Mass Spectrometry
por: Krombholz, Sophia, et al.
Publicado: (2022)

39(th) ISBTI Annual Conference, TRANSCON 2014, Surat Patiala
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_40ctv49dmtef9l172i2kfi4mi2